Why does amylin co-agonism add to a GLP-1 effect rather than duplicate it?

I am asking mechanistically rather than practically — I want the model, not the protocol.

I can predict the outcome but I cannot explain it, which means I will get the next case wrong.

I would like to know how confident the field actually is about this.

Can someone derive this rather than assert it?

GLP-1R is a class B G-protein-coupled receptor signalling predominantly through Gs and cyclic AMP, and most of the interesting pharmacology in this class is about where that signalling happens rather than how hard it is driven.

The Aib substitution at position 8 replaces alanine with α-aminoisobutyric acid, which is sterically hindered enough that dipeptidyl peptidase-4 cannot cleave the N-terminal dipeptide. That single change takes the half-life from minutes to hours. The C18 diacid on a linker at Lys26 then binds albumin reversibly, which both shields the molecule from renal filtration and creates a depot that releases slowly — taking hours to about a week.

What the glucagon arm of a tri-agonist adds is energy expenditure and hepatic fat mobilisation; what it costs is glycaemic control and an increase in heart rate. That is why the tri-agonists show a steeper weight-loss curve and why their development requires more care around cardiac and glycaemic endpoints than a pure GLP-1 agonist does.

The structural basis of semaglutide’s pharmacokinetics — Aib-8, the Arg34Lys substitution and the C18 diacid–AEEA linker at Lys26 — is described in the original medicinal chemistry publication, and it is worth reading once because it makes the design logic explicit[1].

The caveat is that mechanism explains and does not predict. A clean mechanistic story has repeatedly failed to survive a Phase 3 in metabolic medicine.

If you want to reason about a new agent, start from its receptor profile and its half-life. Almost everything else follows.

edited 15 Dec 2025 by lyoph_cake — removed a claim I could not source